NASDAQ:SAGE
Sage Therapeutics Stock News
$11.90
-0.440 (-3.57%)
At Close: May 10, 2024
Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
06:30am, Monday, 05'th Jun 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Sage Therapeutics to Present at Upcoming May Investor Conferences
06:30am, Wednesday, 03'rd May 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Sage Therapeutics, Inc. (SAGE) Q1 2023 Earnings Call Transcript
03:28pm, Tuesday, 02'nd May 2023
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2023 Earnings Conference Call May 2, 2023 8:00 AM ET Company Participants Helen Rubinstein - Director of Investor Relations Barry Greene - Chief Executive Off
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
09:08am, Tuesday, 02'nd May 2023
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $2.46 per share versus the Zacks Consensus Estimate of a loss of $2.50. This compares to loss of $2.07 per share a year ago.
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
06:30am, Tuesday, 18'th Apr 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that
Sage Therapeutics to Present at the Stifel 2023 CNS Days
06:30am, Wednesday, 22'nd Mar 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that
Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?
05:21am, Tuesday, 14'th Mar 2023
Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stren
Sage Therapeutics Looking To FDA Approval Of Zuranolone
06:23am, Tuesday, 21'st Feb 2023
Sage's first approved drug, Zulresso, did not sell well. Zuranolone offers significant improvements for depression over current therapies.
Sage Therapeutics, Inc. (SAGE) Q4 2022 Earnings Call Transcript
01:25pm, Thursday, 16'th Feb 2023
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Helen Rubinstein - Director of Investor Relations Barry Greene - Chief Executi
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates
09:02am, Thursday, 16'th Feb 2023
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st
SAGE Stock: 3.53% Increase Explanation
02:25am, Tuesday, 07'th Feb 2023
The stock price of SAGE Therapeutics Inc (NASDAQ: SAGE) increased by 3.53% in the most recent trading session. This is why.
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
06:30am, Thursday, 02'nd Feb 2023
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a
Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB
12:42pm, Monday, 16'th Jan 2023 Zacks Investment Research
XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.
Biotech's Blockbuster Week: 3 Stocks to Watch
05:32pm, Friday, 13'th Jan 2023 Zacks Investment Research
In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.
Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?
08:25am, Thursday, 12'th Jan 2023 Zacks Investment Research
Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further st
